Sean Mccarthy Sells 118,969 Shares of CytomX Therapeutics (NASDAQ:CTMX) Stock

CytomX Therapeutics, Inc. (NASDAQ:CTMX) CEO Sean Mccarthy sold 118,969 shares of CytomX Therapeutics stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $6.42, for a total value of $763,780.98. Following the completion of the transaction, the chief executive officer owned 1,078,922 shares in the company, valued at $6,926,679.24. This trade represents a 9.93% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

CytomX Therapeutics Price Performance

CytomX Therapeutics stock opened at $4.45 on Friday. CytomX Therapeutics, Inc. has a 12 month low of $0.40 and a 12 month high of $8.21. The business has a 50 day simple moving average of $5.28 and a 200-day simple moving average of $4.12. The stock has a market capitalization of $757.35 million, a PE ratio of -111.25 and a beta of 2.44.

CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings results on Monday, March 16th. The biotechnology company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.14). The company had revenue of $0.66 million for the quarter, compared to analyst estimates of $7.33 million. CytomX Therapeutics had a negative return on equity of 19.77% and a negative net margin of 22.79%. As a group, equities research analysts anticipate that CytomX Therapeutics, Inc. will post -0.05 EPS for the current year.

Hedge Funds Weigh In On CytomX Therapeutics

Large investors have recently made changes to their positions in the stock. Squarepoint Ops LLC lifted its stake in shares of CytomX Therapeutics by 4.5% in the fourth quarter. Squarepoint Ops LLC now owns 49,897 shares of the biotechnology company’s stock valued at $213,000 after purchasing an additional 2,169 shares during the period. Wells Fargo & Company MN grew its position in CytomX Therapeutics by 83.2% during the fourth quarter. Wells Fargo & Company MN now owns 6,605 shares of the biotechnology company’s stock worth $28,000 after buying an additional 3,000 shares during the period. Velan Capital Investment Management LP increased its holdings in CytomX Therapeutics by 6.7% in the third quarter. Velan Capital Investment Management LP now owns 80,000 shares of the biotechnology company’s stock valued at $255,000 after buying an additional 5,000 shares in the last quarter. Farther Finance Advisors LLC purchased a new position in CytomX Therapeutics in the third quarter valued at about $25,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of CytomX Therapeutics during the 4th quarter valued at approximately $35,000. Hedge funds and other institutional investors own 67.77% of the company’s stock.

Key CytomX Therapeutics News

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Multiple high‑profile analyst upgrades and big price‑target increases (Jefferies, Barclays, Guggenheim, Wedbush and others) have pushed positive momentum and attracted buyers. Jefferies raises price target to $16
• Positive Sentiment: Trading volume spiked after the analyst upgrade cycle, suggesting the upgrades translated into real buying interest rather than just headlines. Strong trading volume after upgrades
• Neutral Sentiment: CytomX priced an equity offering to raise about $234 million, which materially extends runway and funding for the pipeline but will dilute existing shareholders. Timing and use of proceeds will determine the net effect. Equity offering announcement
• Neutral Sentiment: Short‑interest reports in recent filings show effectively zero reported short interest (data appears inconsistent/NaN), so short positioning is not clearly driving moves at this time. Short interest data (reporting)
• Negative Sentiment: CytomX missed Q1/quarterly estimates on both EPS and revenue, a concrete near‑term negative that increases uncertainty around execution and near‑term cash generation. Shares down on disappointing earnings
• Negative Sentiment: An analyst cut the Q1 EPS forecast, adding to concerns about near‑term financial performance and guidance. Q1 EPS forecast decreased
• Negative Sentiment: Clustered insider selling on March 17 (CEO Sean McCarthy, CFO Christopher Ogden, SVP Marcia Belvin and others) — sizable block sales by multiple senior executives — is dampening sentiment even if some sales are routine. Insider sales report
• Negative Sentiment: Some sell‑side and independent commentary warn that early clinical data may not yet justify elevated valuations, which could pressure momentum traders and cap further upside until clearer clinical/corporate catalysts arrive. Valuation caution commentary

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. Barclays boosted their price target on shares of CytomX Therapeutics from $10.00 to $16.00 and gave the stock an “overweight” rating in a research note on Thursday. Cantor Fitzgerald raised their price objective on shares of CytomX Therapeutics from $6.00 to $10.00 and gave the company an “overweight” rating in a research report on Wednesday, February 4th. Piper Sandler lifted their price objective on CytomX Therapeutics from $6.50 to $10.00 and gave the company an “overweight” rating in a report on Tuesday, January 20th. Weiss Ratings cut CytomX Therapeutics from a “hold (c-)” rating to a “sell (d)” rating in a research report on Thursday. Finally, HC Wainwright increased their target price on CytomX Therapeutics from $10.00 to $17.00 and gave the stock a “buy” rating in a research note on Monday, March 16th. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $13.22.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.